Based on the Artelo Biosciences Inc stock forecast from 0 analysts, the average analyst target price for Artelo Biosciences Inc is not available over the next 12 months. Artelo Biosciences Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Artelo Biosciences Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Artelo Biosciences Inc’s stock price was USD 0.95. Artelo Biosciences Inc’s stock price has changed by +16.05% over the past week, +0.40% over the past month and -27.47% over the last year.
No recent analyst target price found for Artelo Biosciences Inc
No recent average analyst rating found for Artelo Biosciences Inc
Company Overview Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, pain and inflammation, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. Read Less
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled rec...Read More
Frequently Asked Questions About Artelo Biosciences Inc (ARTL) Stock
Stock Target Advisor's fundamental analysis for Artelo Biosciences Inc's stock is Bearish.
Unfortunately we do not have enough data on ARTL's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ARTL's stock to indicate what its average analyst target is.
ARTL stock's Price/Earning ratio is 116.00.
Our analysis grades ARTL stock's Price / Earning ratio at F. This means that ARTL stock's Price/Earning ratio is above 91% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARTL may be a overvalued for its sector.
The last closing price of ARTL's stock was USD 0.95.
The most recent market capitalization for ARTL is USD 2.70M.
Unfortunately we do not have enough analyst data on ARTL's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Artelo Biosciences Inc's stock.
As per our most recent records Artelo Biosciences Inc has 6 Employees.
Artelo Biosciences Inc's registered address is 505 Lomas Santa Fe, Solana Beach, CA, United States, 92075.
You can get more information about it from Artelo Biosciences Inc's website at https://www.artelobio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Artelo Biosciences Inc (ARTL) Stock
Stock Target Advisor's fundamental analysis for Artelo Biosciences Inc's stock is Bearish.
Unfortunately we do not have enough data on ARTL's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ARTL's stock to indicate what its average analyst target is.
ARTL stock's Price/Earning ratio is 116.00.
Our analysis grades ARTL stock's Price / Earning ratio at F. This means that ARTL stock's Price/Earning ratio is above 91% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARTL may be a overvalued for its sector.
The last closing price of ARTL's stock was USD 0.95.
The most recent market capitalization for ARTL is USD 2.70M.
Unfortunately we do not have enough analyst data on ARTL's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Artelo Biosciences Inc's stock.
As per our most recent records Artelo Biosciences Inc has 6 Employees.
Artelo Biosciences Inc's registered address is 505 Lomas Santa Fe, Solana Beach, CA, United States, 92075.
You can get more information about it from Artelo Biosciences Inc's website at https://www.artelobio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARTL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
